Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8(1):59–73.

Article  CAS  PubMed  Google Scholar 

Nurgali K, Jagoe RT, Abalo R. Editorial: adverse effects of cancer chemotherapy: anything new to improve tolerance and reduce sequelae?? Front Pharmacol. 2018;9: 245.

Article  PubMed  PubMed Central  Google Scholar 

Baidoun F, Elshiwy K, Elkeraie Y, Merjaneh Z, Khoudari G, Sarmini MT, Gad M, Al-Husseini M, Saad A. Colorectal cancer epidemiology: recent trends and impact on outcomes. Curr Drug Targets. 2021;22(9):998–1009.

Article  CAS  PubMed  Google Scholar 

Kashyap D, Pal D, Sharma R, Garg VK, Goel N, Koundal D, Zaguia A, Koundal S, Belay A. Global Increase in Breast Cancer Incidence: Risk Factors and Preventive Measures. BioMed research international. 2022;2022:9605439.

Article  PubMed  PubMed Central  Google Scholar 

Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18(1):155.

Article  PubMed  PubMed Central  Google Scholar 

Yang M, Lin W, Huang J, Mannucci A, Luo H. Novel immunotherapeutic approaches in gastric cancer. Precis Clin Med. 2024;7(4): pbae020.

Article  PubMed  PubMed Central  Google Scholar 

Karami R, Fathi M, Jalali P, Hassannia H, Zarei A, Hojjat-Farsangi M, Jadidi F. The emerging role of TIM-3 in colorectal cancer: a promising target for immunotherapy. Expert Opin Ther Targets. 2024;28(12):1093–115.

Article  CAS  PubMed  Google Scholar 

Takamatsu K, Tanaka N, Hakozaki K, Takahashi R, Teranishi Y, Murakami T, Kufukihara R, Niwa N, Mikami S, Shinojima T. Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy. Nat Commun. 2021;12(1):5547.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Attalla K, Farkas AM, Anastos H, Audenet F, Galsky MD, Bhardwaj N, Sfakianos JP. TIM-3 and TIGIT are possible immune checkpoint targets in patients with bladder cancer. In: Urologic Oncology: Seminars and Original Investigations: 2022. Elsevier; 2022. p. 403–6.

Google Scholar 

Chen Z, Dong D, Zhu Y, Pang N, Ding J. The role of Tim-3/Galectin-9 pathway in T-cell function and prognosis of patients with human papilloma virus-associated cervical carcinoma. FASEB J. 2021;35(3): e21401.

Article  CAS  PubMed  Google Scholar 

Zang K, Hui L, Wang M, Huang Y, Zhu X, Yao B. TIM-3 as a prognostic marker and a potential immunotherapy target in human malignant tumors: a meta-analysis and bioinformatics validation. Front Oncol. 2021;11: 579351.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fernandez S. Listeria monocytogenes as a vector for cancer immunotherapies. University of California, Berkeley; 2024.

Google Scholar 

Zhang C, Xu L, Ma Y, Huang Y, Zhou L, Le H, Chen Z. Increased TIM-3 expression in tumor-associated macrophages predicts a poorer prognosis in non-small cell lung cancer: a retrospective cohort study. J Thorac Dis. 2023;15(3):1433.

Article  PubMed  PubMed Central  Google Scholar 

Zhang X-S, Zhou H-C, Wei P, Chen L, Ma W-H, Ding L, Liang S-C, Chen B-D. Combined TIM-3 and PD-1 blockade restrains hepatocellular carcinoma development by facilitating CD4 + and CD8 + T cell-mediated antitumor immune responses. World J Gastrointest Oncol. 2023;15(12):2138.

Article  PubMed  PubMed Central  Google Scholar 

Das M, Zhu C, Kuchroo VK. Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev. 2017;276(1):97–111.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou E, Huang Q, Wang J, Fang C, Yang L, Zhu M, Chen J, Chen L, Dong M. Up-regulation of Tim-3 is associated with poor prognosis of patients with colon cancer. Int J Clin Exp Pathol. 2015;8(7):8018–27.

PubMed  PubMed Central  Google Scholar 

Chen C, Zhao F, Peng J, Zhao D, Xu L, Li H, Ma S, Peng X, Sheng X, Sun Y. Soluble Tim-3 serves as a tumor prognostic marker and therapeutic target for CD8 + T cell exhaustion and anti-PD-1 resistance. Cell Rep Med. 2024. https://doi.org/10.1016/j.xcrm.2024.101686.

Article  PubMed  PubMed Central  Google Scholar 

Selnø ATH. Biochemical Regulation of the Tim-3-Galectin-9 Immunosuppressive Pathway under Normal Conditions and upon Cell Malignant Transformation. University of Kent (United Kingdom); 2021.

Google Scholar 

Jafarkhani S, Hossein-Nataj H, Eslami-Jouybari M, Ghoreishi M, Asgarian-Omran H. PD-1 and TIM-3 blocking cannot enhance apoptosis of chronic lymphocytic leukemia cells induced by peripheral blood CD8 + T cells. Exp Oncol. 2024;46(4):287–94.

Article  Google Scholar 

Zhang H, Song Y, Yang H, Liu Z, Gao L, Liang X, Ma C. Tumor cell-intrinsic Tim-3 promotes liver cancer via NF-κB/IL-6/STAT3 axis. Oncogene. 2018;37(18):2456–68.

Article  CAS  PubMed  Google Scholar 

Ausejo-Mauleon I, Laspidea V, de la Nava D, Nuin S, Palacios-Alonso D, Marco-Sanz J, Becher O, Jiang L, Filbon MG, Pastor F. DIPG-04. TUMOR CELL-INTRINSIC TIM-3 PROMOTES DIFFUSE INTRINSIC PONTINE GLIOMA TUMORIGENESIS. Neurooncology. 2023;25(Suppl 1):i13.

Google Scholar 

Ausejo-Mauleon I, Labiano S, de la Nava D, Laspidea V, Zalacain M, Marrodán L, García-Moure M, Gonzalez-Huarriz M, Hervás-Corpión I, Dhandapani L. TIM-3 Blockade in diffuse intrinsic Pontine glioma models promotes tumor regression and antitumor immune memory. Cancer Cell. 2023;41(11):1911–26. e1918.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cong Y, Wang X, Wang S, Qiao G, Li Y, Cao J, Jiang W, Cui Y. Tim-3 promotes tube formation and decreases tight junction formation in vascular endothelial cells. Biosci Rep. 2020. https://doi.org/10.1042/BSR20202130.

Article  PubMed  PubMed Central  Google Scholar 

Cong Y, Cui Y, Zhu S, Cao J, Zou H, Martin TA, Qiao G, Jiang W, Yu Z. Tim-3 promotes cell aggressiveness and Paclitaxel resistance through NF-κB/STAT3 signalling pathway in breast cancer cells. Chin J Cancer Res = Chung-kuo Yen Cheng Yen Chiu. 2020;32(5):564–79.

CAS  PubMed  Google Scholar 

Hamel Z, Sanchez S, Standing D, Anant S. Role of STAT3 in pancreatic cancer. Explor Target Anti-tumor Therapy. 2024;5(5):20.

Article  CAS  Google Scholar 

Rébé C, Ghiringhelli F. STAT3, a master regulator of anti-tumor immune response. Cancers (Basel). 2019. https://doi.org/10.3390/cancers11091280.

Article  PubMed  Google Scholar 

Wang Y, Shen Y, Wang S, Shen Q, Zhou X. The role of STAT3 in leading the crosstalk between human cancers and the immune system. Cancer Lett. 2018;415:117–28.

Article  CAS  PubMed  Google Scholar 

Banerjee K, Resat H. Constitutive activation of STAT3 in breast cancer cells: a review. Int J Cancer. 2016;138(11):2570–8.

Article  CAS  PubMed  Google Scholar 

Tomkowicz B, Walsh E, Cotty A, Verona R, Sabins N, Kaplan F, Santulli-Marotto S, Chin CN, Mooney J, Lingham RB, et al. TIM-3 Suppresses Anti-CD3/CD28-Induced TCR Activation and IL-2 Expression through the NFAT Signaling Pathway. PLoS One. 2015;10(10): e0140694.

Article  PubMed  PubMed Central  Google Scholar 

Lee J, Su EW, Zhu C, Hainline S, Phuah J, Moroco JA, Smithgall TE, Kuchroo VK, Kane LP. Phosphotyrosine-dependent coupling of Tim-3 to T-cell receptor signaling pathways. Mol Cell Biol. 2011;31(19):3963–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu F, Liu Y, Chen Z. Tim-3 expression and its role in hepatocellular carcinoma. J Hematol Oncol. 2018;11(1):126.

Article  CAS